PIK3CA and rhabdomyosarcoma: Previous studies have shown that treatment of rhabdomyosarcoma cell lines with Buparlisib (BKM-120), a pan inhibitor of class I PI3K enzymes, inhibited cell growth and proliferation [39,40,41], albeit this compound demonstrated high toxicity and poor activity at tolerable doses.